IQVIA: 3 Key Takeaways for Long-Term Investors

On its third-quarter 2026 earnings call, held on Oct. 27, 2026, IQVIA (NYSE:IQV) reported accelerating revenue growth and raised full-year financial guidance. The contract research organization (a provider that runs clinical trials and data analytics for pharmaceutical companies) is expanding profit margins while capturing record clinical bookings. Three things management said stand out.

1. Net New Clinical Bookings Reached Multiyear Highs

Contract research providers rely on multiyear booking trends to signal long-term revenue direction. Client demand accelerated as funding recovered among emerging biopharma companies, which are biotech firms without commercial products on the market.

For the quarter, the last 12-month net new bookings were $11.7 billion an increase of 14% year over year. And importantly, this metric has been steadily increasing each of the past 5 quarters and points to continued momentum in our business.
-- Michael J. Fedock, Executive Vice President and Chief Financial Officer

2. Artificial Intelligence Deployments Are Deepening Customer Integration

Software tools powered by artificial intelligence allow clients to analyze complex health data and shorten clinical trial timelines. Adoption of these automated tools strengthens customer retention and creates new subscription revenue.

Successful adoption of our AI offerings in commercial organizations within our clients is deepening client trust in IQVIA, And as that trust grows, clients are increasingly looking to us to bring more of our AI enabled capabilities to their organizations.
-- Ari Bousbib, Chairman and Chief Executive Officer

3. Internal Automation Drives Operational Profit Expansion

Profitability expanded despite increased pass-through costs (reimbursed expenses from third-party vendor services that yield no profit margin). Efficiency gains and automated internal workflows offset non-operational costs, keeping margins expanding.

The pass throughs across the enterprise were certainly a headwind on the gross margin line, probably about 70 basis points. So it really highlights the underlying strength in our operational execution.
-- Michael J. Fedock, Executive Vice President and Chief Financial Officer

Looking Ahead

Demand across clinical research and commercial analytics continues to strengthen across regions. Operating momentum remains healthy across core segments as client decision timelines shorten.

The market environment has continued to improve. But our performance improved even more. Our organic growth rates year over year accelerated meaningfully, 2x for commercial and nearly 3x for clinical.
-- Ari Bousbib, Chairman and Chief Executive Officer

The company enters the next quarter with expanding backlogs, higher win rates, and rising client adoption of automated workflow tools. Management relies on pricing discipline and operational efficiency to sustain profitability as biopharma funding rebounds.

We are confident in the momentum that the metrics that we highlighted previously would imply for the future.
-- Michael J. Fedock, Executive Vice President and Chief Financial Officer

The Motley Fool has positions in and recommends Iqvia Holdings. The Motley Fool has a disclosure policy.